- News & Features
Ever wonder what life is like for those living chronic and invisible diseases? Learn about the invisible struggles people with chronic disease face.
Higher MBDA scores yielded statistically significant associations with higher serious infection rates and significantly higher rates of heart disease.
On Dec. 14, Pfizer, which makes tofacitinib (Xeljanz), announced that the FDA had approved the drug for PsA.
In 2017, CreakyJoints lived up to our mantra of “bringing arthritis to its knees", by increasing support, education, advocacy, and research activities.
These findings suggest that there is a window of opportunity to treat patients with undifferentiated arthritis early, to delay subsequent progression to RA.
FDA is investigating serious adverse events involving Limbrel, a product in capsule form currently being marketed as a medical food to manage the metabolic processes associated with osteoarthritis.
Adults with hypertension can lower their blood pressure by consuming less sodium and sticking to the Dietary Approaches to Stop...
More than half of cardiovascular disease patients are being denied access to a new treatment.
UK researchers have found that obese rheumatoid arthritis patients are likelier to be disabled and have lower remission rates.
Starting on November 1st, the Open Enrollment period is the time for everyone to start thinking about health coverage for 2018.
Women with rheumatoid arthritis were 68 percent likelier to develop chronic obstructive pulmonary disease (COPD) than was the general population.